We are live on ! Find out more
WHWK

Whitehawk Therapeutics

48 hedge funds and large institutions have $79.2M invested in Whitehawk Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

46% more capital invested

Capital invested by funds: $54.3M → $79.2M (+$24.9M)

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

17% more funds holding

Funds holding: 4148 (+7)

8.8% more ownership

Funds ownership: 61.18%69.97% (+8.8%)

Holders
48
Holders Change
+7
Holders Change %
+17.07%
% of All Funds
0.58%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
12
Increased
10
Reduced
6
Closed
5
Calls
$7K
Puts
Net Calls
+$7K
Net Calls Change
+$7K
Name Holding Trade Value Shares
Change
Change in
Stake
TRCT
51
Tower Research Capital (TRC)
New York
-$1.51K -797 Closed
Simplex Trading
52
Simplex Trading
Illinois
-$80 -35 Closed

WHWK Hedge Fund Activity: Q4 2025 in Review

48 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2025, worth a combined $79.2M — up 46% from $54.3M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new WHWK positions and 5 closed out — a net gain of 7 holders — while 10 added to existing stakes and 6 trimmed.

The largest buyer was Stempoint Capital, adding an estimated $2.37M. The largest seller was Peapod Lane Capital, exiting entirely with an estimated $577K sold.

  • 48 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2025, up from 41 in Q3 2025.
  • Funds reported $79.2M of Whitehawk Therapeutics stock for Q4 2025, up 46% quarter-over-quarter.
  • 12 funds opened new Whitehawk Therapeutics positions in Q4 2025 and 5 closed out, a net change of +7 holders.
  • The largest Whitehawk Therapeutics buyer in Q4 2025 was Stempoint Capital, an estimated $2.37M added.
  • The largest Whitehawk Therapeutics seller in Q4 2025 was Peapod Lane Capital, an estimated $577K sold.

Based on aggregated 13F filings for Q4 2025.